- 03.09.2025 08:33 CapVest Partners Acquires Stada, Abandoning IPO Strategy
- 02.09.2025 19:45 Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
- 02.09.2025 19:43 Eisai Secures FDA Approval for Leqembi Autoinjector, Enabling At-Home Maintenance Dosing
- 02.09.2025 15:13 Neon Health Secures $6 Million to Enhance Access to Specialty Drugs
- 02.09.2025 15:05 Zenas BioPharma & Royalty Pharma Enter Obexelimab Funding Agreement for up to $300 Million
- 02.09.2025 14:38 FDA Grants RMAT Designation to ETX101 for Dravet Syndrome
- 31.08.2025 19:21 Leadership Changes at Novo Nordisk and Rocket Pharma
- 31.08.2025 08:43 Physician Enthusiasm for Novo’s Wegovy Suggests Swift Uptake in Rezdiffra-Dominated MASH Market
- 31.08.2025 08:34 AbbVie’s Gilgamesh Acquisition: A Strategic Shift to Single-Asset Focus
- 31.08.2025 08:21 Zydus Therapeutics Secures Phase 2b/3 Victory in Liver Disease: A Strategic Move Against Gilead and Ipsen
- 31.08.2025 08:21 BeOne Advances Sonrotoclax: A Potential Breakthrough in Rare B Cell Lymphoma Treatment
- 31.08.2025 07:45 Outlook’s Wet AMD Candidate Faces Second FDA Rejection
- 31.08.2025 07:26 A New Dawn for GCA Treatment
- 30.08.2025 12:42 Turning Cancer on Its Head
- 30.08.2025 12:40 FDA’s Bold Move: Pfizer’s EUA Revoked
- 30.08.2025 12:39 Digital Twins: The Future of Obesity Treatment?
- 30.08.2025 11:15 Navigating Online Pharmacy Risks
- 30.08.2025 11:12 Disaster-Ready: Are We Prepared?